title: [Induction of protective immune responses by a chimeric soluble protein from a recombinant BCG vector candidate vaccine to HIV-1].
abstract: We have been isolated HIV strains from blood specimens of HIV infected individuals in Japan for these 6 years. The number of specimens tested reached approximately 1,700 that ninety percent of them were from hemophiliacs repeatedly injected blood products from the United States. More than 300 of field HIV were successfully isolated from the samples. The isolation rates has decreased to 30 percent in 1993 from 40 percent in 1992, suggesting that treatment with anti-HIV drugs such as AZT and/or ddI may be effective to HIV-infected individuals. Further, both of the viral and genomic sequences of HIV were classified to be clade B virus. The clinical isolates that expressed IHIGPGRAFY sequence at the center of the HIV-V3 domain were found to be neutralized by an anti-clade B-V3 monoclonal antibody, mu 5.5. By individual levels, when asymptomatic seropositives have progressed to disease-states, neutralization core motif of GPGR in approximately 6% of the viruses has changed to GPGG and hydrophilic amino acid changed to hydrophobic amino acid, correlating the loss of binding activity to PND-peptide of Japanese Consensus virus. Further, rapid progressors to HIV-induced diseases showed decreased activity of the binding antibody. By using the Japanese consensus sequence of HIV-1, we successfully constructed chimeric protein secretion vectors by selecting an appropriate insertion site of a carrier protein, and established the PND-peptide secretion system in BCG. The recombinant BCG inoculated guinea pigs were initially screened by delayed-type hypersensitivity (DTH) skin reactions to the PND peptide followed by passive transfer of the DTH by the systemic route.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: National Institute of Health, Tokyo.
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: K
authors.initials: K
authors.lastname: Kitamura
authors.forename: Y
authors.initials: Y
authors.lastname: Okamoto
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Yoshizaki
authors.forename: Y
authors.initials: Y
authors.lastname: Fukushima
authors.forename: S
authors.initials: S
authors.lastname: Naganawa
authors.forename: G
authors.initials: G
authors.lastname: Miyamoto
authors.forename: K
authors.initials: K
authors.lastname: Someya
authors.forename: K
authors.initials: K
authors.lastname: Yamada
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation; D001483:Base Sequence; D006168:Guinea Pigs; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D009163:Mycobacterium bovis / Q000276:immunology*; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000276:immunology; D014162:Transfection
chemical_list: D016915:AIDS Vaccines; D011994:Recombinant Proteins